Trial · NCT02462187
Adverse events180
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 180
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application Site Burn | General disorders | Cohort 1: NVN1000 8% Gel Twice Daily | 1 | 12 | 1 |
| other | Application Site Burn | General disorders | Cohort 2: NVN1000 8% Gel Once Daily | 0 | 23 | 0 |
| other | Application Site Burn | General disorders | Cohort 3: NVN1000 16% Once Daily | 0 | 14 | 0 |
| other | Application Site Burn | General disorders | Cohort 4: NVN1000 24% Once Daily | 0 | 30 | 0 |
| other | Application Site Burn | General disorders | Vehicle Gel Once Daily | 0 | 20 | 0 |
| other | Application Site Burn | General disorders | Vehicle Gel Twice Daily | 0 | 4 | 0 |
| other | Application Site Erosion | General disorders | Cohort 1: NVN1000 8% Gel Twice Daily | 1 | 12 | 1 |
| other | Application Site Erosion | General disorders | Cohort 2: NVN1000 8% Gel Once Daily | 0 | 23 | 0 |
| other | Application Site Erosion | General disorders | Cohort 3: NVN1000 16% Once Daily | 0 | 14 | 0 |
| other | Application Site Erosion | General disorders | Cohort 4: NVN1000 24% Once Daily | 2 | 30 | 3 |
| other | Application Site Erosion | General disorders | Vehicle Gel Once Daily | 0 | 20 | 0 |
| other | Application Site Erosion | General disorders | Vehicle Gel Twice Daily | 0 | 4 | 0 |
| other | Application Site Erythema | General disorders | Cohort 1: NVN1000 8% Gel Twice Daily | 1 | 12 | 1 |
| other | Application Site Erythema | General disorders | Cohort 2: NVN1000 8% Gel Once Daily | 0 | 23 | 0 |
| other | Application Site Erythema | General disorders | Cohort 3: NVN1000 16% Once Daily | 0 | 14 | 0 |
| other | Application Site Erythema | General disorders | Cohort 4: NVN1000 24% Once Daily | 2 | 30 | 2 |
| other | Application Site Erythema | General disorders | Vehicle Gel Once Daily | 0 | 20 | 0 |
| other | Application Site Erythema | General disorders | Vehicle Gel Twice Daily | 0 | 4 | 0 |
| other | Application Site Exfoliation | General disorders | Cohort 1: NVN1000 8% Gel Twice Daily | 0 | 12 | 0 |
| other | Application Site Exfoliation | General disorders | Cohort 2: NVN1000 8% Gel Once Daily | 3 | 23 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02462187/events